Effects of two different brands of ibuprofen on ductus arteriosus closure
Phase 3
- Conditions
- Patent ductus arteriosus.Patent ductus arteriosusQ25.0
- Registration Number
- IRCT20140519017756N48
- Lead Sponsor
- Vice-chancellery for Research, Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Preterm newborn
A size of patent ductus arteriosus that responds to drug therapy
Gestational age of 32 weeks or more
Birth weight 1500 grams and less
Age between 3 and 15 days
Exclusion Criteria
Presence of underlying heart diseases
Major congenital anomalies
Life-threatening sepsis
Renal failure
Pulmonary hemorrhage
Thrombocytopenia below 60,000/mm3
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ductus arteriosus closure. Timepoint: Prior to treatment initiation and three days post-treatment completion. Method of measurement: Echocardiography.
- Secondary Outcome Measures
Name Time Method